Nadine Norton
Has grant
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Discovering aging-associated genetic modifiers and therapies for anthracycline-induced cardiotoxicity
Open Date: 2025-08-01
Close Date: 2029-05-31
Grant: Open
Individualized medicine to predict and prevent chemotherapy-related heart failure
Open Date: 2023-07-01
Close Date: 2026-11-30
Grant: Close
Characterization of TRPC6 to predict and prevent chemotherapy-related heart failure
Open Date: 2022-09-22
Close Date: 2023-08-31
Grant: Close
Characterization of TRPC6 to Predict and Prevent Chemotherapy-Related Cardiomyopathy and Heart Failure in Women
Open Date: 2020-10-01
Close Date: 2021-09-01
Articles (11)
Purpose: CD4 T-cell immunity is associated with improved survival in patients with breast cancer. We previously reported a phase I trial evaluating a folate receptor alpha (FRα) vaccine administered with cyclophosphamide (CP), demonstrating excellent safety and immunogenicity. To simplify the vaccine strategy for ease of use, we report here the results of a randomized phase II trial evaluating a lower vaccine dose alongside the original dose, administered with or without CP pretreatment. Patients and Methods: Patients with triple-negative breast cancer who completed all systemic and local therapies were assigned to receive either low-dose (825 μg) or high-dose (2.5 mg) vaccine peptides plus GM-CSF in six 4-week cycles, with or without CP prior to vaccination. Safety was monitored, and immunogenicity was evaluated before and after vaccination. Results: A total of 80 patients were dosed with vaccine, and 58 patients were evaluable for immunogenicity. Vaccination was well tolerated and elicited immunity in 83% of patients. Levels of FRα-specific T cells were high, persistent, and comparable with T-cell levels against tetanus toxoid. No differences in immunity were observed between the two doses. CP pretreatment also did not affect the immune responses. Recurrences occurred in eight evaluable patients and were unrelated to the treatment arm. No patients died during the study because of their disease. Conclusions: The reduced-dose FRα vaccine is as effective as the original dose and does not require CP to generate maximal immunity. These findings may inform the design of trials testing efficacy in triple-negative breast cancer or other cancers.
Year:
2026
BACKGROUND: TRPC6 (transient receptor potential canonical 6) channels, encoded by the TRPC6 gene, are widely expressed in cardiomyocytes and play a critical role in maintaining intracellular Ca 2 + homeostasis. Variants in TRPC6 are associated with chemotherapy-related cardiomyopathy. Specifically, the TRPC6 A404V polymorphism, with a minor (404 V) allele frequency of 12% in the general population, has been identified in patients undergoing anthracycline therapy. However, the underlying mechanisms remain largely unexplored. METHODS: Using patch-clamp recordings, Ca 2 + imaging, computational analysis, and molecular biology techniques, we assessed the effects of doxorubicin and its metabolite, doxorubicinol, on regulating TRPC6 alanine (A) at position 404 replaced by valine (V; A404V) channel expression and function in a heterologous expression system and native cardiac cells. RESULTS: Both additive and recessive models demonstrated a significant association between the TRPC6 A404V variant and doxorubicin-related cardiomyopathy. The TRPC6 A404V channel exhibited higher membrane expression levels compared with the wild type (WT) control. Patch-clamp recordings showed that both TRPC6 WT and A404V channels remained mostly inactive at baseline. Application of 50 μmol/L 1-oleoyl acetyl-sn-glycerol (OAG), a TRPC6 activator, significantly increased the inward- and outward-current densities of WT and A404V channels. Furthermore, a 24-hour treatment with 0.5 μmol/L doxorubicin enhanced TRPC6 mRNA expression and potentiated the OAG effects on both WT and A404V channels, with a more pronounced response in A404V channels. Treatment with 0.5 μmol/L doxorubicinol had no effect on OAG-induced current densities in either WT or A404V channels. Doxorubicin effects on intracellular Ca 2 + levels were confirmed by Ca 2 + imaging in native cardiac cells. Computational modeling revealed that the A404V mutation induces a conformational change in the OAG-binding pocket, enhancing its interaction with OAG in the A404V protein compared with the WT control. CONCLUSIONS: The TRPC6 A404V is a gain-of-function variant that exhibits enhanced activity in the presence of doxorubicin. Therefore, the TRPC6 A404V variant represents a risk factor for anthracycline-induced cardiotoxicity in patients with cancer.
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Purpose: CD4 T-cell immunity is associated with improved survival in patients with breast cancer. We previously reported a phase I trial evaluating a folate receptor alpha (FRα) vaccine administered with cyclophosphamide (CP), demonstrating excellent safety and immunogenicity. To simplify the vaccine strategy for ease of use, we report here the results of a randomized phase II trial evaluating a lower vaccine dose alongside the original dose, administered with or without CP pretreatment. Patients and Methods: Patients with triple-negative breast cancer who completed all systemic and local therapies were assigned to receive either low-dose (825 μg) or high-dose (2.5 mg) vaccine peptides plus GM-CSF in six 4-week cycles, with or without CP prior to vaccination. Safety was monitored, and immunogenicity was evaluated before and after vaccination. Results: A total of 80 patients were dosed with vaccine, and 58 patients were evaluable for immunogenicity. Vaccination was well tolerated and elicited immunity in 83% of patients. Levels of FRα-specific T cells were high, persistent, and comparable with T-cell levels against tetanus toxoid. No differences in immunity were observed between the two doses. CP pretreatment also did not affect the immune responses. Recurrences occurred in eight evaluable patients and were unrelated to the treatment arm. No patients died during the study because of their disease. Conclusions: The reduced-dose FRα vaccine is as effective as the original dose and does not require CP to generate maximal immunity. These findings may inform the design of trials testing efficacy in triple-negative breast cancer or other cancers.
Year:
2026
Enzalutamide and abiraterone are hormonal treatments that improve survival in metastatic castration‐resistant prostate cancer. Identifying genetic variants associated with the clearance of these drugs may aid in improved dosing and outcomes. We performed genetic association studies of enzalutamide and abiraterone oral clearance in the Alliance A031201 clinical trial. Genome‐wide genotyping was performed with the primary analysis limited to European‐descent participants. Pharmacogene metabolic phenotypes were estimated using PyPGx and Stargazer. Associations of metabolic activity groups for CYP3A4 , CYP3A5 , CYP2C19 and SLCO1B1 with enzalutamide clearance ( N = 706) and CYP3A4 , SLCO2B1 and UGT1A4 with abiraterone clearance ( N = 323) were tested by linear regression. Targeted SNP associations were assessed for abiraterone clearance at loci proximal to major metabolizing genes. Full genome‐wide association studies were performed for both sets of clearance values. No significant associations were identified between metabolic phenotypes and enzalutamide or abiraterone oral clearance SNPs in the SULT2A1 5′ flanking region were significantly associated with lower abiraterone clearance, (rs296373, minor allele frequency = 0.15, β = −0.457, p = 3.2E‐06). Liver protein and liver and adrenal gland gene expression QTL databases indicated significantly lower SULT2A1 expression patterns for individuals carrying associated alleles, likely explaining the lower abiraterone oral clearance. CYP2C8*3 was associated with higher enzalutamide clearance ( p = 0.012), but this was not significant after correction for multiple testing. This study is the first to identify the genetic association of SULT2A1, known to be involved in the metabolism of steroids in the liver and adrenal glands, with abiraterone clearance. Genetic variation in SULT2A1 may be useful to inform personalized dosing of abiraterone. ClinicalTrials.gov Identifier: NCT01949337
Year:
2025
570 Background: Major histocompatibility complex class I (MHC I) plays a critical role in immune surveillance by binding peptides derived from intracellular proteins and presenting them on the cell surface for recognition by CD8+ T cells. Loss or downregulation of MHC I expression has been identified as a key mechanism of immune evasion in cancers. Here, we evaluated MHC I expression and outcomes in all subtypes of breast cancer (BC). Methods: 9,038 BC samples were analyzed via NGS (592-gene panel, NextSeq; WES/WTS, NovaSeq; Caris Life Sciences, Phoenix, AZ), including triple-negative BC (TNBC) 3,038, HER2-positive (HER2+) 1,082, and hormone receptor-positive (HR+HER2-) 4,918. Immune cell fractions were estimated using WTS deconvolution (Quantiseq). MHC I ( HLA-A / HLA-B / HLA-C )-high (H) and -low (L) were classified by RNA expression above or below the 25th percentile. Real-world overall survival (OS) was derived from insurance claims and calculated from tissue collection to last contact using Kaplan-Meier. NanoString IO360 was performed in 114 samples from the FinXX trial (NCT00114816). Statistical significance was assessed using chi-square, Mann-Whitney U, ANOVA, and Cox regression with multiple comparison adjustments (q<.05). Results: TNBC had higher expression of HLA-A and HLA-B (median TPM: 169 and 191) compared to HER2+ (146.6 and 170, q<0.05) and HR+HER2- (141.7 and 157.5, q<0.05). However, there was no significant difference in HLA-C expression across 3 BC subtypes. In TNBC, MHC I-H tumors had higher frequencies of PD-L1 positivity (66.2% vs. 13.1%) as well as higher infiltration of B cells (4.5% vs. 3.2%), M1 macrophages (5% vs. 1.5%), M2 macrophages (4% vs. 2.1%), Tregs (2.8% vs. 0.8%), CD8 + T cells (1.8% vs. 0%), dendritic cells (3.2% vs. 2.8%), higher T-cell inflamed score (137 vs. -144), and IFN g score (0.02 vs. -0.49) compared to MHC I-L TNBC (all q<.05). MHC I-H TNBC was associated with significant improvement in median OS (30.1 vs. 15.2 months, HR 0.55, 95% CI 0.46-0.65, p<0.0001). However, this survival difference was not observed in patients with MHC I-H vs. MHC I-L in HER2+ (HR 1.04, 95% CI 0.74-1.47, p = 0.81) and HR+HER2- (HR 0.87, 95% CI 0.75-1.02, p= 0.09) BC subtypes. We further validated the MHC I expression in the FinXX trial. Similarly, patients with MHC I-H had significant improvement in recurrence-free survival (HR 0.27, 95%CI 0.11-0.66, p = 0.002) and OS (HR 0.23, 95% CI 0.09-0.57, p = 0.0005) compared to MHC I-L. Conclusions: Our findings demonstrate that higher MHC I expression is associated with higher immune infiltration and improved outcomes in TNBC but not in HER2+ or HR+HER2- BC subtypes. These results suggest that MHC I expression plays a critical role in the tumor microenvironment of TNBC. Future studies are needed to evaluate the prognostic value and potential therapeutic target of MHC I in TNBC. Support: Breast Cancer Research Foundation, Bankhead Coley, W81XWH-18-1-0564. Clinical trial information: NCT00114816 .
Year:
2025
Background: While immune checkpoint inhibitor (ICI) has significantly improved outcomes in patients with early-stage triple-negative breast cancer (TNBC), patients with residual disease after pembrolizumab-based neoadjuvant chemotherapy continue to have particularly poor outcomes. Patients with larger amounts of residual disease with residual cancer burden (RCB)-III and RCB-II had extremely poor outcomes, with 72.5% and 25.5% of patients developing recurrence within the first 3 years, respectively. Recent breakthroughs in identifying personal neoantigens via a comprehensive analysis of cancer sequencing data have brought increased attention to neoantigen cancer vaccines. Personalized cancer vaccines targeting neoantigens have shown early promising results in melanoma. While neoantigens have recently been investigated in some cancer types, the current neoantigen prediction algorithms have often focused on the MHC class-I subtype, single nucleotide mutations (SNM), small insertions, and deletions (INDEL). We recently developed an informatics workflow, REAL-neo, for the identification, quality control (QC), and prioritization of both class-I and class-II human leukocyte antigen (HLA) bound neoantigens that arise from somatic SNM, INDEL, aberrant RNA splicing, and gene fusions, generating much more potent neoantigen candidates. Furthermore, we demonstrated robust T-cell response and prolonged survival by combining ICI and cancer vaccines in preclinical models. This phase I/II clinical trial is in progress to assess the safety, feasibility, and immunogenicity of personalized neoantigen vaccines in combination with pembrolizumab in patients with advanced solid cancers with a phase II extension cohort in patients with early-stage TNBC with residual disease after neoadjuvant chemotherapy. Methods: Key eligibility criteria include females ≥ 18 years old with histologically confirmed stage I-III TNBC (ER<10%, PR <10%, and HER2 negative per ASCO/CAP guideline. Patients with evidence of residual disease ≥ 1 cm after neoadjuvant pembrolizumab-based chemotherapy on imaging will be enrolled in the pre-screening phase prior to surgery to collect fresh frozen samples for sequencing. After surgery, patients with histologically confirmed RCB-II and RCB-III will be pre-registered, and patient samples will be sequenced to identify patient-specific neoantigens using the REAL-neo algorithm. Patients will continue with standard-of-care therapy based on the treating physician's choice. Once PNeoVCA vaccine production is completed, eligible patients will receive the vaccine consisting of up to 20 peptides delivered with GM-CSF as an adjuvant. PNeoVCA will be administered with 4-5 peptides at 300 mcg/peptide and GM-CSF 125 mcg per injection site in each limb in combination with Pembrolizumab 200 mg i.v. PNeoVCA will be given via subcutaneous injection on days 1, 4, 8, 15, and 21, with boosters in weeks 5 and 8. Clinical trial information: NCT05269381 Citation Format: Saranya Chumsri, Yanyan Lou, Qian Shi, Jordan Reynolds, Brian Necela, Nadine Norton, Rohit Rao, Pooja Advani, Kostandinos Sideras, Michael Gustafson, Yan Asmann, Keith Knutson. Phase I/II of Personalized Neoantigen Peptide-Based Vaccine (PNeoVCA) in Combination with Pembrolizumab in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P3-10-16.
Year:
2025
Background: Immune checkpoint inhibitor (ICI) in combination with chemotherapy has become the standard of care for early-stage and first-line metastatic triple-negative breast cancer (TNBC) patients. TNBC disproportionately affected African Americans and Hispanic patients. Previous studies prior to ICI approval in TNBC demonstrated racial disparity with worse outcomes in these groups of patients. However, the impact of race on the outcomes of TNBC patients treated with ICI remains unknown. In this study, we analyzed the National Cancer Database (NCDB) to evaluate the clinical characteristics and outcomes of TNBC patients from different racial groups. Methods: The NCDB patient database from 2004-2017 was used. Continuous variables were summarized using sample mean and standard deviation, and categorical and discrete variables were summarized using count and percentage of patients. Independent samples t-test or ANOVA were used to compare continuous variables, and categorical and discrete variables were compared using a chi-square test. Patient survival by race was calculated using the Kaplan-Meier method. Associations of race with death were evaluated using unadjusted Cox regression models with death as the outcome. Hazard ratios (HRs) were estimated. All statistical tests were two-sided. Statistical analyses were performed using R Statistical Software. Results: A total of 2015 patients were included, consisting of 71.4% White, 19.7% African American, and 8.9% Hispanic. The African American and Hispanic cohorts had more patients < 60 years old than the White cohort, representing 63.9%, 66.1%, and 56.8%, respectively (p = 0.005). African Americans and Hispanics also had more patients with Charlson-Deyo scores above 0 compared to Whites, representing 17.2%, 16.1%, and 10.6% of their respective cohorts (p = 0.003). African Americans and Hispanics tended to receive treatment at academic centers compared to Whites, representing 47.0%, 55.2%, and 34.0%, respectively (p < 0.001). Additionally, a greater proportion of African Americans and Hispanics received treatment in metro areas compared to White patients, representing 93.3%, 96.0%, and 85.5% of their respective cohorts (p < 0.001). There was no significant difference in insurance coverage between races (p = 0.333). In contrast, the different race cohorts presented similar distributions of clinical features, with no significant differences in tumor grade (p = 0.276), tumor size (p = 0.285), lymph node status (p = 0.422), lymphovascular invasion status (p = 0.088), clinical and pathologic staging (p = 0.096), and whether they received chemotherapy (p = 0.230), radiation therapy (p = 0.587), and surgery (p = 0.242). For stage II-III TNBC, there were 538 White, 142 African American, and 62 Hispanic patients who received at least 1 dose of ICI. Using Kaplan-Meier analysis, African American patients (n = 142) had significantly worse overall survival (OS) compared to whites (HR = 1.362, p = 0.012). For patients with Stage IV TNBC receiving ICI, there were 108 Whites, 30 African American, and 12 Hispanic patients. There was a trend toward worse outcomes in African American patients when compared to whites (HR = 1.950, p = 0.210). There was no significant difference in patient survival when comparing Hispanic/other patients with whites in any stage of TNBC while receiving ICI (HR = 0.956, p = 0.777 for Stage II and III; HR = 2.089, p = 0.200 for Stage IV). Conclusion: Despite similar clinical characteristics, African-American TNBC patients receiving ICI had significantly worse outcomes compared to Whites. Future studies are needed to further validate these results and elucidate the biological basis for the racial disparity observed with ICI treatment in TNBC patients. Citation Format: Andrew Liu, Nadine Norton, Keith Knutson, Saranya Chumsri. The impact of race on outcomes of immune checkpoint inhibitor in triple-negative breast cancer patients: NCDB data analysis [abstract]. In: P
Year:
2025
Year:
2025
Collaborators (14)
Stephanie L. Graff
Brown University
James Cerhan
Professor of Epidemiology
Mayo Clinic Rochester
Deanna Kroetz
Dean and Professor
Ohio State University
Keith Knutson
Mayo Clinic Florida
Priyanka Sharma
Associate Professor
University of Kansas Medical Center
Hao-Jie Zhu
Professor
University of Michigan
Richard Kenney
Chief Medical Officer
-
Konstantinos N Lazaridis
-
Joseph A. Sparano
Chief, Division of Hematology/Oncology; Deputy Director, Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
Aziza Nassar
Consultant/Professor of Pathology
Medical University of South Carolina
Xiaolei Xu
Professor
Mayo Clinic Minnesota
Daniel Hertz
University of Michigan
Jogarao Gobburu
Professor
University of Maryland
Tong Lu
Associate Consultant/Associate Professor
Mayo Clinic Minnesota
Make your next move.
Prepare your application
Review drafts before you send them.